Product image of Inkodess (Drospirenone, Ethinylestradiol) supplied by GNH India

Inkodess

Active Ingredient:
Drospirenone, Ethinylestradiol
Origin:
EU

Inkodess (Drospirenone, Ethinylestradiol)

Drospirenone, the active ingredient in Inkodess, is a combined oral contraceptive presented as a tablet for oral use. It works together with ethinylestradiol to prevent pregnancy and to regulate menstrual cycles in women of reproductive age. The formulation is approved for prescription use in the European Union.

GNH India supplies Inkodess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this hormonal contraceptive, benefiting customers with consistent batch release and regulatory compliance.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Inkodess, a combined oral contraceptive, is used to manage reproductive hormone pathways.
  • Pregnancy prevention: provides reliable contraception for women of childbearing potential.
  • Menstrual cycle regulation: helps achieve more predictable bleeding patterns.
  • Management of dysmenorrhea: reduces menstrual pain associated with primary dysmenorrhea.
  • Treatment of acne: may improve mild acne linked to hormonal fluctuations.
  • Premenstrual syndrome relief: alleviates mood swings, breast tenderness and other PMS symptoms.

How It Works

  • Inkodess combines drospirenone, a synthetic progestogen, with ethinylestradiol, a synthetic estrogen. The estrogen component suppresses the mid‑cycle surge of luteinizing hormone, while drospirenone blocks progesterone receptors and exerts anti‑androgenic activity. Together they inhibit ovulation, thicken cervical mucus to impede sperm penetration, and induce endometrial changes that reduce the likelihood of implantation.

Side Effects

Inkodess may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

  • Nausea
  • Breast tenderness
  • Headache
  • Spotting between periods

Serious or Rare Side Effects

  • Blood clots (deep‑vein thrombosis, pulmonary embolism)
  • Stroke or myocardial infarction
  • Severe hypertension
  • Liver dysfunction or jaundice

Precautions & Warnings

  • Before prescribing Inkodess, clinicians should consider several safety factors.
  • Assess cardiovascular risk: evaluate history of thrombosis, smoking, or hypertension.
  • Screen for liver disease: avoid use in active hepatic impairment.
  • Consider age and smoking status: women over 35 who smoke should not use this product.
  • Review medication history: avoid concomitant use with strong enzyme inducers.
  • Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Avoid Interactions

Inkodess can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

  • Anticoagulants (e.g., warfarin): may reduce contraceptive efficacy.
  • Antiepileptics (e.g., carbamazepine, phenytoin): increase hormone metabolism.
  • Rifampicin and other antibiotics: lower plasma hormone levels.

Moderate Interactions (Monitor Closely)

  • Antifungals (e.g., ketoconazole): may raise hormone concentrations.
  • St. John’s wort: may decrease contraceptive effectiveness.

Frequently Asked Questions

Inkodess is a prescription‑only combined oral contraceptive containing drospirenone and ethinylestradiol. It is indicated for preventing pregnancy and for regulating menstrual cycles in women of reproductive age, helping to achieve more predictable bleeding patterns.

Drospirenone acts as a synthetic progestogen with anti‑androgenic and antimineralocorticoid properties. It blocks progesterone receptors, thickens cervical mucus, and contributes to the suppression of ovulation when combined with ethinylestradiol, thereby preventing fertilisation and implantation.

The dosing regimen for Inkodess is determined by the prescribing clinician. Typically, it is taken once daily at the same time for a 21‑day active tablet course followed by a hormone‑free interval, but the exact schedule should follow the prescriber’s instructions.

Inkodess is contraindicated during pregnancy because it is designed to prevent conception. If pregnancy occurs, the product should be discontinued. Limited data are available for breastfeeding; clinicians usually advise using alternative contraception and discuss risks with the patient.

To order Inkodess, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inkodess combines drospirenone, which has anti‑androgenic and antimineralocorticoid activity, with ethinylestradiol. Compared with older progestins, drospirenone may offer benefits such as reduced water retention and a lower risk of acne, but the overall efficacy and safety profile remain comparable to other combined oral contraceptives.

Inkodess tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Inkodess is taken orally as a tablet, usually once each day at the same time. Patients should follow the prescribed cycle—typically 21 active tablets followed by a hormone‑free interval—while adhering to any specific instructions from their healthcare provider.

The most serious risks include venous thromboembolism, arterial thrombosis (such as stroke or myocardial infarction), severe hypertension, and liver disorders. Patients should be monitored for signs of these conditions and discontinue use if they occur.

Inkodess is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant or breastfeeding. It should also be avoided by smokers over 35 years of age.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Drospirenone, Ethinylestradiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT